DUBLIN--(BUSINESS WIRE)--Sep. 13, 2018--
Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in
near-vision restoration, will participate in the XXXVI Congress of the
European Society of Cataract and Refractive Surgeons (ESCRS), Europe's
leading organization for cataract and refractive surgeons, to be held in
Vienna, Austria from September 22-26, 2018.
“We have made significant progress in 2018, including our submission in
the second quarter of 2018 to the U.S. Food and Drug Administration of
our Premarket approval containing 24-month data on our Investigational
Device Exemption subjects,” said Mark Yung, Chairman and CEO of Presbia.
“Participating in ESCRS supports the commercialization efforts of our
Microlens in Germany.”
Mr. Yung will be available for one-on-one meetings at booth number B200
during the ESCRS.
Presbia will also participate in the German Ophthalmological Society
Congress to be held in Bonn, Germany from September 27-29, 2018. The
German Ophthalmological Society is the medical scientific association of
ophthalmology in Germany, uniting physicians and scientists in treatment
and research in ophthalmology.
Presbia representatives will be available at booth number K.54 during
the German Ophthalmological Society Congress to answer any questions.
This release contains “forward-looking statements” made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
These statements are typically preceded by words such as “believes,”
“expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar
expressions. Such forward-looking statements only speak as of the date
of this press release and Presbia assumes no obligation to update the
information included in this press release. Statements made in this
press release that are forward-looking in nature may involve risks and
uncertainties, including, but not limited to, the factors listed under
“Risk Factors” in our annual report on Form 10-K for the year ended
December 31, 2017, quarterly reports on Form 10-Q, and other reports
that Presbia files with the SEC. Accordingly, readers are cautioned that
any such forward-looking statements are not guarantees and are subject
to certain risks, uncertainties and assumptions that are difficult to
predict. Although Presbia believes that the expectations reflected in
such forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements. Unless
otherwise required by law, Presbia also disclaims any obligation to
update its view of any such risks or uncertainties or to announce
publicly the result of any revisions to the forward-looking statements
made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005275/en/
Source: Presbia PLC
Richard T. Fogarty, 949-502-7036